Cargando…

Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer

BACKGROUND: Because patient-derived xenografts (PDXs) are grown in immunodeficient mouse strains, PDXs are regarded as lacking an immune microenvironment. However, whether patients’ immune cells co-exist in PDXs remains uncharacterized. METHODS: We cultured small pieces of lung PDX tissue in media c...

Descripción completa

Detalles Bibliográficos
Autores principales: Pu, Xingxiang, Zhang, Ran, Wang, Li, Chen, Yungchang, Xu, Yi, Pataer, Apar, Meraz, Ismail M., Zhang, Xiaoshan, Wu, Shuhong, Wu, Lin, Su, Dan, Mao, Weimin, Heymach, John V., Roth, Jack A., Swisher, Stephen G., Fang, Bingliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260563/
https://www.ncbi.nlm.nih.gov/pubmed/30477533
http://dx.doi.org/10.1186/s12967-018-1704-3
_version_ 1783374821447434240
author Pu, Xingxiang
Zhang, Ran
Wang, Li
Chen, Yungchang
Xu, Yi
Pataer, Apar
Meraz, Ismail M.
Zhang, Xiaoshan
Wu, Shuhong
Wu, Lin
Su, Dan
Mao, Weimin
Heymach, John V.
Roth, Jack A.
Swisher, Stephen G.
Fang, Bingliang
author_facet Pu, Xingxiang
Zhang, Ran
Wang, Li
Chen, Yungchang
Xu, Yi
Pataer, Apar
Meraz, Ismail M.
Zhang, Xiaoshan
Wu, Shuhong
Wu, Lin
Su, Dan
Mao, Weimin
Heymach, John V.
Roth, Jack A.
Swisher, Stephen G.
Fang, Bingliang
author_sort Pu, Xingxiang
collection PubMed
description BACKGROUND: Because patient-derived xenografts (PDXs) are grown in immunodeficient mouse strains, PDXs are regarded as lacking an immune microenvironment. However, whether patients’ immune cells co-exist in PDXs remains uncharacterized. METHODS: We cultured small pieces of lung PDX tissue in media containing human interleukin-2 and characterized the proliferated lymphocytes by flow cytometric assays with antibodies specific for human immune cell surface markers. Presence of immune cells in PDXs was also determined by immunohistochemical staining. RESULTS: Human tumor-infiltrating lymphocytes (TILs) were cultured from nine of 25 PDX samples (36%). The mean time of PDX growth in immunodeficient mice before obtaining TILs in culture was 113 days (range 63–292 days). The TILs detected in PDXs were predominantly human CD8(+) T cells, CD4(+) T cells, or CD19(+) B cells, depending on cases. DNA fingerprint analysis showed that the TILs originated from the same patients as the PDXs. Further analysis of two PDX-derived CD8(+) T cells showed that they were PD-1(−), CD45RO(+), and either CD62L(+) or CD62L(−), suggesting they were likely memory T cells. Immunohistochemical staining showed that human T cells (CD8(+) or CD4(+)), B cells (CD19(+)), and macrophages (CD68(+)) were present in stroma or intraepithelial cancer structures and that human PD-L1 was expressed in stromal cells. Moreover, the patient-derived immune cells in PDX can be passaged to the F2 generation and may migrate to spleens of PDX-bearing mice. CONCLUSIONS: Patient-derived immune cells co-exist in early passages of PDXs in some lung cancer PDX models. The CD8(+) cells from PDXs were likely memory T cells. These results suggest that PDXs can be used for evaluating the functionality of immune components in tumor microenvironments. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12967-018-1704-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6260563
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62605632018-11-30 Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer Pu, Xingxiang Zhang, Ran Wang, Li Chen, Yungchang Xu, Yi Pataer, Apar Meraz, Ismail M. Zhang, Xiaoshan Wu, Shuhong Wu, Lin Su, Dan Mao, Weimin Heymach, John V. Roth, Jack A. Swisher, Stephen G. Fang, Bingliang J Transl Med Research BACKGROUND: Because patient-derived xenografts (PDXs) are grown in immunodeficient mouse strains, PDXs are regarded as lacking an immune microenvironment. However, whether patients’ immune cells co-exist in PDXs remains uncharacterized. METHODS: We cultured small pieces of lung PDX tissue in media containing human interleukin-2 and characterized the proliferated lymphocytes by flow cytometric assays with antibodies specific for human immune cell surface markers. Presence of immune cells in PDXs was also determined by immunohistochemical staining. RESULTS: Human tumor-infiltrating lymphocytes (TILs) were cultured from nine of 25 PDX samples (36%). The mean time of PDX growth in immunodeficient mice before obtaining TILs in culture was 113 days (range 63–292 days). The TILs detected in PDXs were predominantly human CD8(+) T cells, CD4(+) T cells, or CD19(+) B cells, depending on cases. DNA fingerprint analysis showed that the TILs originated from the same patients as the PDXs. Further analysis of two PDX-derived CD8(+) T cells showed that they were PD-1(−), CD45RO(+), and either CD62L(+) or CD62L(−), suggesting they were likely memory T cells. Immunohistochemical staining showed that human T cells (CD8(+) or CD4(+)), B cells (CD19(+)), and macrophages (CD68(+)) were present in stroma or intraepithelial cancer structures and that human PD-L1 was expressed in stromal cells. Moreover, the patient-derived immune cells in PDX can be passaged to the F2 generation and may migrate to spleens of PDX-bearing mice. CONCLUSIONS: Patient-derived immune cells co-exist in early passages of PDXs in some lung cancer PDX models. The CD8(+) cells from PDXs were likely memory T cells. These results suggest that PDXs can be used for evaluating the functionality of immune components in tumor microenvironments. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12967-018-1704-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-11-26 /pmc/articles/PMC6260563/ /pubmed/30477533 http://dx.doi.org/10.1186/s12967-018-1704-3 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Pu, Xingxiang
Zhang, Ran
Wang, Li
Chen, Yungchang
Xu, Yi
Pataer, Apar
Meraz, Ismail M.
Zhang, Xiaoshan
Wu, Shuhong
Wu, Lin
Su, Dan
Mao, Weimin
Heymach, John V.
Roth, Jack A.
Swisher, Stephen G.
Fang, Bingliang
Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
title Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
title_full Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
title_fullStr Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
title_full_unstemmed Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
title_short Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
title_sort patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260563/
https://www.ncbi.nlm.nih.gov/pubmed/30477533
http://dx.doi.org/10.1186/s12967-018-1704-3
work_keys_str_mv AT puxingxiang patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer
AT zhangran patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer
AT wangli patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer
AT chenyungchang patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer
AT xuyi patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer
AT pataerapar patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer
AT merazismailm patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer
AT zhangxiaoshan patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer
AT wushuhong patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer
AT wulin patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer
AT sudan patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer
AT maoweimin patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer
AT heymachjohnv patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer
AT rothjacka patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer
AT swisherstepheng patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer
AT fangbingliang patientderivedtumorimmunemicroenvironmentsinpatientderivedxenograftsoflungcancer